Arudein

Arudein may be available in the countries listed below.

Ingredient matches for Arudein

Piroxicam

Piroxicam is reported as an ingredient of Arudein in the following countries:

• Japan

International Drug Name Search

Frenasma

Frenasma may be available in the countries listed below.

Ingredient matches for Frenasma

Ketotifen

Ketotifen is reported as an ingredient of Frenasma in the following countries:

• Romania

Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Frenasma in the following countries:

• Greece

International Drug Name Search

Alkala

Alkala may be available in the countries listed below.

Ingredient matches for Alkala

Sodium Bicarbonate

Sodium Bicarbonate is reported as an ingredient of Alkala in the following countries:

• Germany

International Drug Name Search

Propiomazine

In the US, Propiomazine is a member of the drug class miscellaneous anxiolytics, sedatives and hypnotics.

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N05CM06

CAS registry number (Chemical Abstracts Service)

0000362-29-8

Chemical Formula

C20-H24-N2-O-S

Molecular Weight

340

Therapeutic Categories

Antiemetic

Hypnotic and sedative agent

Antihistaminic agent

Chemical Name

1-Propanone, 1-[10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl]-

Foreign Names

• Propiomazinum (Latin)
• Propiomazin (German)
• Propiomazine (French)
• Propiomazina (Spanish)

Generic Names

• Propiomazine (OS: BAN, USAN, DCF)
• CB 1678 (IS)
• Wy 1359 (IS)

Brand Name

• Propavan
  Sanofi-Aventis, Sweden

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Totamol

Totamol may be available in the countries listed below.

Ingredient matches for Totamol

Atenolol

Atenolol is reported as an ingredient of Totamol in the following countries:

• Malta


• Oman

International Drug Name Search

Donacom

Donacom may be available in the countries listed below.

Ingredient matches for Donacom

Glucosamine

Glucosamine is reported as an ingredient of Donacom in the following countries:

• Belgium

Glucosamine sulfate (a derivative of Glucosamine) is reported as an ingredient of Donacom in the following countries:

• Norway

Glucosamine sulfate sodium chloride (a derivative of Glucosamine) is reported as an ingredient of Donacom in the following countries:

• Sweden

International Drug Name Search

Dallergy Sustained-Release and Long-Acting Tablets

Pronunciation: KLOR-fen-IR-a-meen/FEN-il-EF-rin/METH-skoe-POL-a-meen
Generic Name: Chlorpheniramine/Phenylephrine/Methscopolamine
Brand Name: Examples include Aerohist Plus and Dallergy

Dallergy Sustained-Release and Long-Acting Tablets are used for:

Relieving congestion, sneezing, runny nose, and itchy, watery eyes due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.

Dallergy Sustained-Release and Long-Acting Tablets are an antihistamine, decongestant, and anticholinergic combination. It works by blocking histamine, a substance in the body that causes sneezing, runny nose, and watery eyes. It also relieves nasal congestion by shrinking the nasal mucous membranes, which promotes nasal drainage, and dries the chest by decreasing lung secretions.

Do NOT use Dallergy Sustained-Release and Long-Acting Tablets if:

• you are allergic to any ingredient in Dallergy Sustained-Release and Long-Acting Tablets


• you are pregnant or breast-feeding


• you take sodium oxybate (GHB) or you have taken furazolidone or a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days


• you have a history of narrow-angle glaucoma, blockage in the stomach or intestines, peptic ulcer disease, intestinal or bowel problems, difficulty urinating, inflammation of the esophagus from reflux disease, difficulty swallowing, or uncontrolled bleeding


• you have severe heart disease or severe high blood pressure

Contact your doctor or health care provider right away if any of these apply to you.

Before using Dallergy Sustained-Release and Long-Acting Tablets:

Some medical conditions may interact with Dallergy Sustained-Release and Long-Acting Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you are taking or have taken medicine for high blood pressure or depression in the last 14 days


• if you have diabetes, an enlarged prostate, a history of bladder or kidney problems, high blood pressure, diarrhea, asthma, nerve problems, heart problems, blood clots, a hiatal hernia, an adrenal gland tumor, glaucoma or increased pressure in the eye, breathing problems during sleep, myasthenia gravis (muscle weakness), lung problems, liver problems, Down syndrome, blood vessel problems, or an overactive thyroid

Some MEDICINES MAY INTERACT with Dallergy Sustained-Release and Long-Acting Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Alpha-blockers (eg, guanethidine, methyldopa, prazosin), beta-blockers (eg, atenolol), diuretics (eg, furosemide, hydrochlorothiazide), furazolidone, or MAOIs (eg, phenelzine) because the risk of high or low blood pressure may be increased


• Alkalizers (eg, calcium or magnesium antacids), anticholinergics (eg, atropine, benztropine, dicyclomine), carbonic anhydrase inhibitors (eg, acetazolamide), ergotamine, sodium bicarbonate, or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Dallergy Sustained-Release and Long-Acting Tablets's side effects


• Bromocriptine, catechol-O-methyltransferase (COMT) inhibitors (eg, entacapone), certain stimulants (eg, doxapram, pseudoephedrine), cocaine, digoxin, droxidopa, potassium chloride, or sodium oxybate ( GHB) because the risk of their side effects may be increased by Dallergy Sustained-Release and Long-Acting Tablets


• Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Dallergy Sustained-Release and Long-Acting Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dallergy Sustained-Release and Long-Acting Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Dallergy Sustained-Release and Long-Acting Tablets:

Use Dallergy Sustained-Release and Long-Acting Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Dallergy Sustained-Release and Long-Acting Tablets by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.


• Swallow Dallergy Sustained-Release and Long-Acting Tablets whole. Do not break, crush, or chew before swallowing. Some brands of Dallergy Sustained-Release and Long-Acting Tablets may be broken in half before taking. If you have difficulty swallowing the whole tablet, ask your pharmacist if your brand of medicine may be broken in half.


• Do not take Dallergy Sustained-Release and Long-Acting Tablets at the same time as antacids, certain medicines for diarrhea (eg, attapulgite, bismuth, kaolin, pectin), or ketoconazole. Take these medicines 2 or 3 hours before or after you take Dallergy Sustained-Release and Long-Acting Tablets.


• If you miss a dose of Dallergy Sustained-Release and Long-Acting Tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Dallergy Sustained-Release and Long-Acting Tablets.

Important safety information:

• Dallergy Sustained-Release and Long-Acting Tablets may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Dallergy Sustained-Release and Long-Acting Tablets with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Dallergy Sustained-Release and Long-Acting Tablets; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.


• If your symptoms do not get better within 7 days or if you develop a high fever or persistent headache, check with your doctor.


• Dallergy Sustained-Release and Long-Acting Tablets may interfere with certain lab tests. Be sure your doctor and lab personnel know you are taking Dallergy Sustained-Release and Long-Acting Tablets.


• Dallergy Sustained-Release and Long-Acting Tablets may interfere with skin allergy tests. If you are scheduled for a skin test, talk to your doctor. You may need to stop taking Dallergy Sustained-Release and Long-Acting Tablets for a few days before the tests.


• Dallergy Sustained-Release and Long-Acting Tablets may cause dry mouth. To relieve dry mouth, suck on sugarless hard candy or ice chips, chew sugarless gum, drink water, or use a saliva substitute.


• Dallergy Sustained-Release and Long-Acting Tablets may make your eyes more sensitive to sunlight. It may help to wear sunglasses.


• Dallergy Sustained-Release and Long-Acting Tablets may reduce sweating. Do not become overheated in hot weather or while you are being active; heatstroke may occur.


• Do not take diet or appetite control medicines while you are taking Dallergy Sustained-Release and Long-Acting Tablets without checking with your doctor.


• If you have trouble sleeping, ask your doctor or pharmacist about the best time of the day to take Dallergy Sustained-Release and Long-Acting Tablets.


• Diabetes patients - Dallergy Sustained-Release and Long-Acting Tablets may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.


• Use Dallergy Sustained-Release and Long-Acting Tablets with caution in the ELDERLY; they may be more sensitive to its effects.


• Dallergy Sustained-Release and Long-Acting Tablets should not be used in CHILDREN younger than 6 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dallergy Sustained-Release and Long-Acting Tablets while you are pregnant. Do not use Dallergy Sustained-Release and Long-Acting Tablets during labor or delivery because it may cause harm to the fetus. Dallergy Sustained-Release and Long-Acting Tablets are found in breast milk. Do not breast-feed while taking Dallergy Sustained-Release and Long-Acting Tablets.

Possible side effects of Dallergy Sustained-Release and Long-Acting Tablets:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Blurred vision; clumsiness; constipation; dizziness; drowsiness; dry mouth, nose, or throat; excitability or irritability (especially in children); flushing; giddiness; headache; lack of energy; nausea; nervousness; tearing; trouble sleeping; unusual tiredness or weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; difficulty swallowing; fast or irregular heartbeat; hallucinations; mental or mood changes; pounding in the chest; sore throat with fever; trouble urinating; unusual bleeding or bruising; vomiting.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Dallergy side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include deep sleep or loss of consciousness; hot or cool skin; irregular heartbeat; irritability, anxiety, or panic; large pupils; numbness or tingling in the arms or legs; seizures; slowed or shallow breathing; vomiting.

Proper storage of Dallergy Sustained-Release and Long-Acting Tablets:

Store Dallergy Sustained-Release and Long-Acting Tablets at room temperature, between 59 and 86 degrees F (15 and 30 degrees C) in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dallergy Sustained-Release and Long-Acting Tablets out of the reach of children and away from pets.

General information:

• If you have any questions about Dallergy Sustained-Release and Long-Acting Tablets, please talk with your doctor, pharmacist, or other health care provider.


• Dallergy Sustained-Release and Long-Acting Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dallergy Sustained-Release and Long-Acting Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Dallergy resources

• Dallergy Side Effects (in more detail)
• Dallergy Use in Pregnancy & Breastfeeding
• Dallergy Drug Interactions
• Dallergy Support Group
• 4 Reviews for Dallergy - Add your own review/rating

Compare Dallergy with other medications

• Nasal Congestion
• Rhinitis

DesOwen 2 oz

Generic Name: desonide topical (DES oh nide)

Brand Names: Delonide, Desonate, DesOwen, DesOwen 2 oz, DesOwen Lotion 4 oz Kit, LoKara, Tridesilon, Verdeso

What is DesOwen 2 oz (desonide topical)?

Desonide is a topical (for the skin) steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.

Desonide topical is used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.

Desonide topical may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about DesOwen 2 oz (desonide topical)?

Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.

Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with desonide topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period. Contact your doctor if your condition does not improve after 2 weeks of using this medicine, or if you develop signs of a bacterial, fungal, or viral skin infection.

What should I discuss with my healthcare provider before using DesOwen 2 oz (desonide topical)?

Do not use this medication if you are allergic to desonide.

Before using desonide topical, tell your doctor if you are allergic to any drugs, or if you have any type of skin infection.

Also tell your doctor if you have diabetes. Topical steroid medicines absorbed through the skin may increase the glucose (sugar) levels in your blood or urine.

FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether desonide topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period.

How should I use DesOwen 2 oz (desonide topical)?

Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.

Wash your hands before and after using desonide topical, unless you are using the medication to treat the skin on your hands.

Apply a small amount to the affected area and rub it gently into the skin. Do not use this medication over a large area of skin.

Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with desonide topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Contact your doctor if your condition does not improve after 2 weeks of using this medicine, or if you develop signs of a bacterial, fungal, or viral skin infection. It is important to use desonide topical regularly to get the most benefit.

To be sure this medication is not causing harmful effects with long-term use, you may need blood tests. Do not miss any scheduled appointments.

Store desonide topical at room temperature away from moisture and heat. Keep from freezing.

What happens if I miss a dose?

Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and use the medicine at the next regularly scheduled time. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of desonide is not expected to produce life-threatening symptoms. However, long-term use of high steroid doses can lead to symptoms such as thinning skin, easy bruising, changes in the shape or location of body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.

What should I avoid while using DesOwen 2 oz (desonide topical)?

Desonide topical should not be used to treat any skin condition your doctor has not prescribed it for.

Avoid getting this medication in your eyes. If contact does occur, rinse with water. Do not use desonide topical on broken or infected skin. Also avoid using this medication in open wounds.

DesOwen 2 oz (desonide topical) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have severe irritation of any treated skin, or if you show signs of absorbing desonide topical through your skin, such as:

• 
  

  blurred vision, or seeing halos around lights;

  
  


• 
  

  mood changes;

  
  


• 
  

  sleep problems (insomnia);

  
  


• 
  

  weight gain, puffiness in your face; or

  
  


• 
  

  muscle weakness, feeling tired.

  
  

Less serious side effects may include:

• 
  

  mild skin itching, redness, burning, or peeling;

  
  


• 
  

  dryness or scaly skin;

  
  


• 
  

  thinning or softening of your skin;

  
  


• 
  

  skin rash or irritation around your mouth;

  
  


• 
  

  swollen hair follicles;

  
  


• 
  

  changes in color of treated skin;

  
  


• 
  

  blisters, pimples, or crusting of treated skin; or

  
  


• 
  

  stretch marks.

  
  

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect DesOwen 2 oz (desonide topical)?

It is not likely that other drugs you take orally or inject will have an effect on topically applied desonide topical. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

More DesOwen 2 oz resources

• DesOwen 2 oz Side Effects (in more detail)
• DesOwen 2 oz Use in Pregnancy & Breastfeeding
• DesOwen 2 oz Drug Interactions
• DesOwen 2 oz Support Group
• 5 Reviews for DesOwen 2 oz - Add your own review/rating

• DesOwen Cream MedFacts Consumer Leaflet (Wolters Kluwer)


• DesOwen Cream Kit Cream MedFacts Consumer Leaflet (Wolters Kluwer)


• Desonate Consumer Overview


• Desonate Advanced Consumer (Micromedex) - Includes Dosage Information


• Desonate Gel MedFacts Consumer Leaflet (Wolters Kluwer)


• Desonate Prescribing Information (FDA)


• Desowen Prescribing Information (FDA)


• LoKara Prescribing Information (FDA)


• LoKara Lotion MedFacts Consumer Leaflet (Wolters Kluwer)


• Verdeso Prescribing Information (FDA)


• Verdeso Consumer Overview


• Verdeso Foam MedFacts Consumer Leaflet (Wolters Kluwer)

Compare DesOwen 2 oz with other medications

• Atopic Dermatitis
• Dermatitis
• Eczema
• Psoriasis

Where can I get more information?

• Your pharmacist can provide more information about desonide topical.

See also: DesOwen 2 oz side effects (in more detail)

Vildagliptin

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A10BH02

CAS registry number (Chemical Abstracts Service)

0274901-16-5

Chemical Formula

C17-H25-N3-O2

Molecular Weight

303

Therapeutic Category

Oral antidiabetic agent, dipeptidyl peptidase-4 (DPP-4) inhibitor, gliptin

Chemical Names

(S)-{[(3-Hydroxyadamantan-1-yl)amino]acetyl}pyrrolidin-2-carbonitril (IUPAC)

(2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile (WHO)

2-Pyrrolidinecarbonitrile, 1-(((3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)amino)acetyl)-, (2S)-

Foreign Names

• Vildagliptinum (Latin)
• Vildagliptin (German)
• Vildagliptine (French)
• Vildagliptina (Spanish)

Generic Names

• Vildagliptin (OS: USAN)
• DPP-728 (IS)
• DPP-728A (IS)
• LAF-237 (IS)
• NVP-DPP-728 (IS)
• NVP-LAF-237 (IS)

Brand Names

• Eucreas (Vildagliptin and Metformin)
  Novartis, Germany; Novartis, Denmark; Novartis, Finland; Novartis, France; Novartis, United Kingdom; Novartis, Greece; Novartis, Ireland; Novartis, Netherlands; Novartis, Norway; Novartis, Sweden; Novartis, Slovenia; Novartis Europharm, Austria



• Galvumet (Vildagliptin and Metformin)
  Novartis, Switzerland



• Galvus
  Dexa Medica, Indonesia; Novartis, Bahrain; Novartis, Switzerland; Novartis, Germany; Novartis, Finland; Novartis, France; Novartis, United Kingdom; Novartis, Greece; Novartis, Indonesia; Novartis, Ireland; Novartis, Italy; Novartis, Netherlands; Novartis, Norway; Novartis, Sweden; Novartis, Slovenia; Novartis Europharm, Austria; Novartis Europharm Ltd., Denmark



• Icandra (Vildagliptin and Metformin)
  Novartis, Germany



• Jalra
  Novartis, Germany; Novartis, Greece; Novartis, Slovakia



• Xiliarx
  Novartis, Slovakia

International Drug Name Search

Glossary

IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Apo-Desmopressin

Apo-Desmopressin may be available in the countries listed below.

Ingredient matches for Apo-Desmopressin

Desmopressin

Desmopressin acetate (a derivative of Desmopressin) is reported as an ingredient of Apo-Desmopressin in the following countries:

• Canada

International Drug Name Search

Neotinil

Neotinil may be available in the countries listed below.

Ingredient matches for Neotinil

Paromomycin

Paromomycin sulfate (a derivative of Paromomycin) is reported as an ingredient of Neotinil in the following countries:

• Dominican Republic

International Drug Name Search

Sulpiride Teva

Sulpiride Teva may be available in the countries listed below.

Ingredient matches for Sulpiride Teva

Sulpiride

Sulpiride is reported as an ingredient of Sulpiride Teva in the following countries:

• France

International Drug Name Search

Atracurium Gemepe

Atracurium Gemepe may be available in the countries listed below.

Ingredient matches for Atracurium Gemepe

Atracurium Besilate

Atracurium Besilate is reported as an ingredient of Atracurium Gemepe in the following countries:

• Argentina

International Drug Name Search

Roseol

Roseol may be available in the countries listed below.

Ingredient matches for Roseol

Loxoprofen

Loxoprofen sodium salt (a derivative of Loxoprofen) is reported as an ingredient of Roseol in the following countries:

• Japan

International Drug Name Search

Talipexole

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0101626-70-4

Chemical Formula

C10-H15-N3-S

Molecular Weight

209

Therapeutic Categories

Treatment of Parkinson's disease

Dopamine agonist

Chemical Name

6-Allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine

Foreign Names

• Talipexolum (Latin)
• Talipexol (German)
• Talipexole (French)
• Talipexol (Spanish)

Generic Names

• Alefexole (IS)
• B-HT 920 (IS)
• Alefexole hydrochloride (IS)

Brand Name

• Domin
  Boehringer Ingelheim, Japan

International Drug Name Search

Glossary

IS	Inofficial Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Baciject

Baciject may be available in the countries listed below.

Ingredient matches for Baciject

Bacitracin

Bacitracin is reported as an ingredient of Baciject in the following countries:

• Canada

International Drug Name Search

Interome

Interome may be available in the countries listed below.

Ingredient matches for Interome

Cefpirome

Cefpirome sulfate (a derivative of Cefpirome) is reported as an ingredient of Interome in the following countries:

• Indonesia

International Drug Name Search

Rennie Antacidum

Rennie Antacidum may be available in the countries listed below.

Ingredient matches for Rennie Antacidum

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Rennie Antacidum in the following countries:

• Poland

Magnesium Carbonate

Magnesium Carbonate is reported as an ingredient of Rennie Antacidum in the following countries:

• Poland

International Drug Name Search

Depakote ER Extended-Release Tablets

Pronunciation: dye-VAL-proe-ex
Generic Name: Divalproex
Brand Name: Depakote ER

Life-threatening liver failure has occurred in patients taking Depakote ER Extended-Release Tablets. Children younger than 2 years old are at increased risk of developing life-threatening liver damage, especially those on more than 1 medicine to treat seizures and those with metabolic disorders, severe seizure disorders accompanied by retardation, or organic brain disease. Contact your doctor immediately if you or your child experiences a general feeling of discomfort, sluggishness, weakness, severe drowsiness, swelling of the face, loss of appetite, vomiting, or loss of seizure control. Liver function tests may be performed before and during therapy with Depakote ER Extended-Release Tablets. Be sure to keep all doctor and lab appointments.

Depakote ER Extended-Release Tablets can cause severe birth defects if it is used during pregnancy. Contact your doctor if you become pregnant or think you may be pregnant while taking Depakote ER Extended-Release Tablets. Depakote ER Extended-Release Tablets comes with an additional patient leaflet, "Important Information for Women Who Could Become Pregnant." Read it carefully.

Cases of life-threatening inflammation of the pancreas have occurred with the use of Depakote ER Extended-Release Tablets. Report any stomach pain, nausea, vomiting, or loss of appetite to your doctor at once.

Depakote ER Extended-Release Tablets are used for:

Controlling certain types of seizures in the treatment of epilepsy. It is also used to treat the manic phase of bipolar disorder (manic-depressive illness), and prevent migraine headaches. It may also be used for other conditions as determined by your doctor.

Depakote ER Extended-Release Tablets are an anticonvulsant. It works by reducing or preventing the number of seizures by controlling the abnormal activity of nerve impulses in the brain and central nervous system. Exactly how it works to treat bipolar disorder and migraine headache is not known.

Do NOT use Depakote ER Extended-Release Tablets if:

• you are allergic to any ingredient in Depakote ER Extended-Release Tablets


• you have liver problems or a urea cycle disorder

Contact your doctor or health care provider right away if any of these apply to you.

Video: Treatment for Depression

Treatments for depression are getting better everyday and there are things you can start doing right away.

Before using Depakote ER Extended-Release Tablets:

Some medical conditions may interact with Depakote ER Extended-Release Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, are breast-feeding, or are of childbearing age


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of alcohol abuse, liver problems, metabolic disease, blood disease, HIV infection, cytomegalovirus (CMV) infection, high blood levels of ammonia or glutamine, low body temperature, low levels of albumin, brain problems (eg, organic brain disease), mental retardation, inflammation of the pancreas, kidney problems, or low levels of white blood cells, or if you are scheduled for surgery


• if you have a history of ornithine transcarbamylase deficiency or unexplained coma


• if you have a family history of urea cycle disorders or unexplained infant deaths


• if you have a history of mental or mood problems (eg, depression), or suicidal thoughts or actions


• if you take any other medicine for seizures

Some MEDICINES MAY INTERACT with Depakote ER Extended-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Benzodiazepines (eg, diazepam), carbamazepine, erythromycin, felbamate, fluoxetine, guanfacine, isoniazid, ketoconazole, risperidone, or salicylates (eg, aspirin) because the risk of serious side effects of Depakote ER Extended-Release Tablets, including changes in vision or other vision problems, clumsiness or unsteadiness, drowsiness, nausea, or vomiting, may be increased


• Clonazepam because the risk of seizures may be increased


• Topiramate because the risk of high ammonium levels, brain problems, or an unusual drop in body temperature may be increased


• Acyclovir, cancer medicines, carbapenem antibiotics (eg, ertapenem, imipenem, meropenem), cholestyramine, hydantoins (eg, phenytoin), mefloquine, nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen), oral contraceptives (eg, birth control pills), or rifampin because they may decrease Depakote ER Extended-Release Tablets's effectiveness


• Anticoagulants (eg, warfarin), barbiturates (eg, phenobarbital), ethosuximide, lamotrigine, methylphenidate, primidone, tolbutamide, tricyclic antidepressants (eg, amitriptyline), or zidovudine because the risk of their side effects may be increased by Depakote ER Extended-Release Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Depakote ER Extended-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Depakote ER Extended-Release Tablets:

Use Depakote ER Extended-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with Depakote ER Extended-Release Tablets. Talk to your pharmacist if you have questions about this information.


• Take Depakote ER Extended-Release Tablets by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.


• Swallow Depakote ER Extended-Release Tablets whole. Do not break, crush, or chew before swallowing.


• Taking Depakote ER Extended-Release Tablets at the same time each day will help you remember to take it.


• Do not stop taking Depakote ER Extended-Release Tablets suddenly, especially if you are taking Depakote ER Extended-Release Tablets to prevent seizures. Suddenly stopping Depakote ER Extended-Release Tablets may cause severe seizures to occur. If you need to stop Depakote ER Extended-Release Tablets, your doctor will gradually lower your dose.


• Continue to take Depakote ER Extended-Release Tablets even if you feel well. Do not miss any doses. Depakote ER Extended-Release Tablets works best when there is a constant level of it in your body.


• If you miss a dose of Depakote ER Extended-Release Tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Depakote ER Extended-Release Tablets.

Important safety information:

• Depakote ER Extended-Release Tablets may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Depakote ER Extended-Release Tablets with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Depakote ER Extended-Release Tablets; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Tell your doctor or dentist that you take Depakote ER Extended-Release Tablets before you receive any medical or dental care, emergency care, or surgery.


• Inflammation of the pancreas is a potentially life-threatening illness associated with Depakote ER Extended-Release Tablets. Symptoms include stomach pain, vomiting, or loss of appetite. Contact your doctor at once if any of these symptoms occur.


• Patients who take Depakote ER Extended-Release Tablets may be at increased risk for suicidal thoughts or actions. The risk may be greater in patients who have had suicidal thoughts or actions in the past. Patients who have bipolar (manic-depressive) illness may also have an increased risk for suicidal thoughts or actions. Watch patients who take Depakote ER Extended-Release Tablets closely. Contact the doctor at once if new, worsened, or sudden symptoms, such as depressed mood; anxious, restless, irritable behavior; panic attacks; or any unusual change in mood or behavior occur. Contact the doctor right away if any signs of suicidal thoughts or actions occur.


• Depakote ER Extended-Release Tablets may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.


• Diabetes patients - Depakote ER Extended-Release Tablets may cause the results of some tests for urine ketones to be wrong. Ask your doctor before you change your diet or the dose of your diabetes medicine.


• Depakote ER Extended-Release Tablets may increase the ammonia levels in your blood. Contact your doctor right away if you experience unexplained sluggishness and vomiting or mental changes.


• Depakote ER Extended-Release Tablets may cause an unusual drop in body temperature (hypothermia). Symptoms may include confusion, lack of energy, loss of coordination, shivering, slow heartbeat, slow or shallow breathing, slurred speech, or unusual drowsiness. Contact your doctor right away if you have any of these symptoms.


• Depakote ER Extended-Release Tablets may interfere with certain lab tests, including thyroid function. Be sure your doctor and lab personnel know you are taking Depakote ER Extended-Release Tablets


• Lab tests, including complete blood cell counts, blood ammonia levels, and liver function, may be performed while you use Depakote ER Extended-Release Tablets. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Depakote ER Extended-Release Tablets with caution in the ELDERLY; they may be more sensitive to its effects, especially drowsiness.


• Depakote ER Extended-Release Tablets should be used with extreme caution in CHILDREN younger than 10 years old; safety and effectiveness in these children have not been confirmed. CHILDREN younger than 2 years old may be at increased risk of serious liver problems.


• PREGNANCY and BREAST-FEEDING: Depakote ER Extended-Release Tablets has been shown to cause harm to the fetus. Use an effective form of birth control while you take Depakote ER Extended-Release Tablets. If you think you may be pregnant or if you wish to become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Depakote ER Extended-Release Tablets while you are pregnant. Depakote ER Extended-Release Tablets are found in breast milk. Do not breast-feed while you are taking Depakote ER Extended-Release Tablets.

Possible side effects of Depakote ER Extended-Release Tablets:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Change in appetite; constipation; diarrhea; dizziness; drowsiness; hair loss; headache; indigestion; nausea; stomach cramps or pain; trouble sleeping; vomiting; weakness; weight changes.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); abnormal thinking; change in menstrual period; changes in behavior; chest pain; confusion; dark, tarry, or bloody stools; dark urine; difficulty speaking; difficulty urinating or other urination problems; extreme tiredness; fast or irregular heartbeat; hallucinations; hearing loss; involuntary movements of the arms and legs; involuntary movements or chewing movements of the face, jaw, mouth, or tongue; joint pain; lack of energy; loss of appetite; loss of coordination; loss of seizure control; memory loss; new or worsening mental or mood changes (eg, aggressiveness, agitation, anxiety, depression, exaggerated feeling of well-being, hostility, impulsiveness, inability to sit still, irritability, panic attacks, restlessness); nosebleed; pounding in the chest; red, swollen, blistered, or peeling skin; severe or persistent nausea, vomiting, or stomach pain; shortness of breath; suicidal thoughts or actions; swelling of the arms or legs; symptoms of infection (eg, fever, chills, sore throat); tremor; unusual bleeding or bruising; unusual weakness; vision changes or blurred vision; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Depakote ER side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include deep sleep; drowsiness; irregular heartbeat; loss of consciousness.

Proper storage of Depakote ER Extended-Release Tablets:

Store Depakote ER Extended-Release Tablets at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Depakote ER Extended-Release Tablets out of the reach of children and away from pets.

General information:

• If you have any questions about Depakote ER Extended-Release Tablets, please talk with your doctor, pharmacist, or other health care provider.


• Depakote ER Extended-Release Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Depakote ER Extended-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Depakote ER resources

• Depakote ER Side Effects (in more detail)
• Depakote ER Dosage
• Depakote ER Use in Pregnancy & Breastfeeding
• Drug Images
• Depakote ER Drug Interactions
• Depakote ER Support Group
• 32 Reviews for Depakote ER - Add your own review/rating

Compare Depakote ER with other medications

• Bipolar Disorder
• Epilepsy
• Hyperekplexia
• Mania
• Migraine Prevention

Floran

Floran may be available in the countries listed below.

Ingredient matches for Floran

Isoflurane

Isoflurane is reported as an ingredient of Floran in the following countries:

• Bahrain


• Egypt


• Iraq


• Jordan


• Kuwait


• Lebanon


• Libya


• Oman


• Qatar


• Saudi Arabia


• Sudan


• Syria


• Tunisia


• United Arab Emirates


• Yemen

International Drug Name Search

Metronidazol SAD

Metronidazol SAD may be available in the countries listed below.

Ingredient matches for Metronidazol SAD

Metronidazole

Metronidazole is reported as an ingredient of Metronidazol SAD in the following countries:

• Denmark

International Drug Name Search

Maxiclear Relief

Maxiclear Relief may be available in the countries listed below.

Ingredient matches for Maxiclear Relief

Phenylephrine

Phenylephrine hydrochloride (a derivative of Phenylephrine) is reported as an ingredient of Maxiclear Relief in the following countries:

• New Zealand

International Drug Name Search

Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension

Pronunciation: DEX-brome-fen-IR-a-meen/FEN-il-EF-rin/pir-IL-a-meen
Generic Name: Dexbrompheniramine/Phenylephrine/Pyrilamine
Brand Name: Poly Tan D

Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension is used for:

Relieving symptoms of sinus congestion, pressure, runny nose, and sneezing due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.

Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension is an antihistamine and decongestant combination. The antihistamines work by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, which relieves congestion and pressure.

Do NOT use Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension if:

• you are allergic to any ingredient in Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension


• you have severe high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems


• you are taking sodium oxybate (GHB) or you have taken furazolidone or a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension:

Some medical conditions may interact with Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a fast, slow, or irregular heartbeat


• if you have a history of asthma; lung problems (eg, emphysema); sleep apnea; adrenal gland problems (eg, adrenal gland tumor); heart problems; high blood pressure; diabetes; blood vessel problems; stroke; glaucoma or increased pressure in the eye; a blockage of your bladder, stomach, or intestines; ulcers; trouble sleeping; trouble urinating; an enlarged prostate or other prostate problems; seizures; kidney problems; thyroid problems; or phenylketonuria

Some MEDICINES MAY INTERACT with Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased


• Beta-blockers (eg, propranolol), catechol-O-methyltransferase (COMT) inhibitors (eg, tolcapone), furazolidone, indomethacin, MAOIs (eg, phenelzine ), sodium oxybate (GHB), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension's side effects


• Bromocriptine or hydantoins (eg, phenytoin) because the risk of their side effects may be increased by Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension


• Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension:

Use Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension by mouth with or without food.


• Shake well before each use.


• Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.


• If you miss a dose of Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension.

Important safety information:

• Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Check with your doctor before you drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Do not take diet or appetite control medicines while you are taking Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension without checking with your doctor.


• Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension has dexbrompheniramine, pyrilamine, and phenylephrine in it. Before you start any new medicine, check the label to see if it has an antihistamine or a decongestant in it too. If it does or if you are not sure, check with your doctor or pharmacist.


• Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.


• If your symptoms do not get better within 5 to 7 days or if they get worse, check with your doctor.


• Some of these products contain phenylalanine. If you must have a diet that is low in phenylalanine, ask your pharmacist if it is in your product.


• Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.


• Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension may interfere with skin allergy tests. If you are scheduled for a skin test, talk to your doctor. You may need to stop taking Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension for a few days before the tests.


• Tell your doctor or dentist that you take Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension before you receive any medical or dental care, emergency care, or surgery.


• Use Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension with caution in the ELDERLY; they may be more sensitive to its effects, especially confusion, dizziness, drowsiness, dry mouth, excitability, low blood pressure, and trouble urinating.


• Caution is advised when using Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension in CHILDREN; they may be more sensitive to its effects, especially excitability.


• Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension should not be used in CHILDREN younger than 2 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension while you are pregnant. Do not take Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension in the third trimester of pregnancy. Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension is found in breast milk. Do not breast-feed while taking Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension.

Possible side effects of Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension:

All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; diarrhea; dizziness; drowsiness; dry mouth; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blurred vision or other vision changes; difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; mood or mental changes; persistent trouble sleeping; restlessness; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; tremor.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Dexbrompheniramine/Phenylephrine/Pyrilamine side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; ringing in the ears; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular breathing; unusually fast, slow, or irregular heartbeat.

Proper storage of Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension:

Store Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension out of the reach of children and away from pets.

General information:

• If you have any questions about Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension, please talk with your doctor, pharmacist, or other health care provider.


• Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dexbrompheniramine/Phenylephrine/Pyrilamine Suspension. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Dexbrompheniramine/Phenylephrine/Pyrilamine resources

• Dexbrompheniramine/Phenylephrine/Pyrilamine Side Effects (in more detail)
• Dexbrompheniramine/Phenylephrine/Pyrilamine Use in Pregnancy & Breastfeeding
• Dexbrompheniramine/Phenylephrine/Pyrilamine Drug Interactions
• Dexbrompheniramine/Phenylephrine/Pyrilamine Support Group
• 0 Reviews for Dexbrompheniramine/Phenylephrine/Pyrilamine - Add your own review/rating

Compare Dexbrompheniramine/Phenylephrine/Pyrilamine with other medications

• Nasal Congestion

Omeoformula 1 Adiposity

OMEOFORMULA®1-ADIPOSITY (Homeopathic complex preparation) INJECTION SC, ID, IM

1. INDICATIONS AND USAGE

1.1.    Treatment  of total body adiposity

1.2.    Treatment of localized adiposity

It is helpful to combine the treatment with oral detoxification therapy, in order to facilitate the elimination of the toxic load, activated by the injection therapy. Patients should also incorporate dietary modifications to facilitate weight loss.

2. DOSAGE AND ADMINISTRATION

2.1.    Treatment of total body adiposity for IM application: 1 vial 1-3 times a week according to severity and clinic evolution.

2.2.    Treatment of localized adiposity using mesotherapy technique: Apply 0,3 ml for each point. Using a 13 mm, 30G or a 4 mm, 27G needle, make the classic intradermal injections utilizing mesotherapy technique.

Application points: Apply to the affected area (abdomen, lower and upper limbs, gluteus muscles)or at acupuncture points.

Standard  protocol consists of one session a week for 5-7 weeks. For prolonged treatments, 2 sessions for the first week, 1 session a week for 1 month and then 1 session a month are recommended.

Discard unused solution.

2.3.    Opening of Vials: Use sterile needles and sterile syringe. Do not reuse. Do not use if foreign particles are present. Draw 1 cc of air into syringe, insert needle into vial inject air and withdraw the solution into the syringe.

3. DOSAGE FORMS AND STRENGTHS

3.1.    Injectable solution for subcutaneneous, intradermal, or intramuscular  administration. Pharmaceutical form: 2 ml glass vials.

3.2.    Each ingredient is attenuated according to the Homeopathic Pharmacopeia of United States.

Active ingredients: a-Ketoglutaricum acidum 6X; Adeps suillus 10X; Artery 6X; Barium oxalosuccinate 6X; Calcarea fluorica 10X; Calcarea fluorica 30X; Calcarea fluorica 200X; Carduus marianus 6X; Cis-Aconitic acid 6X; Citricum acidum 6X; DL malic acid 6X; Fucus vesiculosus 10X; Fucus vesiculosus 30X; Fucus vesiculosus 200X; Fumaricum acidum 6X; Hypophysis 10X; Hypophysis 30X; Hypophysis 200X; Magnesium gluconate 6X; Manganum phosphoricum 6X; Natrum oxalaceticum 6X; Natrum pyruvicum 6X;  Nicotinamidum 6X; Sarsaparilla 6X; Succinicum acidum 6X; Sulphur 12X; Thyroidinum 10X.

Inactive ingredient: Sterile isotonic sodium chloride solution.

4. CONTRAINDICATIONS

4.1.    There is no history of hypersensitivity to OMEOFORMULA®1-ADIPOSITY. However patients with a known hypersensitivity to any ingredient should be tested before use. Make a spot injection (0.1ml) into the forearm and observe for any reactions for 1 hour.

5. WARNINGS AND PRECAUTIONS

5.1.    Be sure to disinfect the area before application. Skin disinfection helps avoid infection at the site of administration that can result from saprophytic bacteria (i.e. atypical mycobacteria, staphylococcus genus) that may be present on the skin.

5.2.    Skin disinfection is required before application. Saprophytic bacteria may produce injection site abscesses with improper skin preparation.

6. ADVERSE REACTIONS

6.1.    The most common mild adverse reaction is slight reddening at the injection site due to the mechanical effect of the needle or a superficial skin reaction of mild erythema.

7. DRUG INTERACTIONS

7.1.    None Known.

8. USE IN SPECIFIC POPULATIONS

8.1    Pregnancy:  Pregnancy  category  C.  Animal  reproduction  studies  have  not  been conducted  with  OMEOFORMULA®1-ADIPOSITY.  OMEOFORMULA®1-ADIPOSITY should  not  be  administered  to  a pregnant woman. 

8.2    Nursing mothers:    It is not known whether any of the ingredients in OMEOFORMULA®1-ADIPOSITY  are  secreted  in  human milk.  However, since many drugs are secreted in human milk, caution should be exercised when OMEOFORMULA®1-ADIPOSITY is administered to a nursing woman.

8.3    Pediatric use: OMEOFORMULA®1-ADIPOSITY is  safe  to use  in adults 14 years and older.

8.4    Geriatric use: No restrictions.

9. DRUG ABUSE AND DEPENDENCE

9.1.    No Known.

10. OVERDOSAGE

10.1.    No Known.

11. DESCRIPTION

OMEOFORMULA®1- ADIPOSITY is a sterile solution made with isotonic sodium chloride solution.

OMEOFORMULA®1-ADIPOSITY formulation is based  on classical Homeopathy and  each ingredient has been selected according to the homeopathic description as referred to in Materia Medica

•    Fucus vesiculosus and Thyroidinum improve oxidative metabolic processes. Hypophysis and Adeps suillus enhance immune response against adiposities.  Sulfur, Carduus marianus, and Sarsaparilla permits the centrifugation of the connective tissue toxins,  the hepatic catabolism of fats, and activation of renal activity; 

•    Artery, and Calcarea fluorica act on tissue tonification  by stimulating increased vascularisation, combating exhaustion of the matrix. The Krebs cycle intermediates provide general stimulation of the cell emphasizing triglyceride hydrolysis (Fumaric acid), drainage (Malic acid) and support of connective tissue structure (alpa Keto- glutaric acid).

12. CLINICAL PHARMACOLOGY

12.1.    Mechanism of Action

The medication acts through a low-dose enzymatic mechanism.

12.2.    Pharmacodynamics

The physiological effects of OMEOFORMULA®1- ADIPOSITY is    are due to the effects of the ingredients according to their description in the Homeopathic Materia Medica.

12.3.    Pharmacokinetics

Homeopathic attenuation  provides complete bioavability of the active ingredients.

13. NONCLINICAL TOXICOLOGY

13.1.    OMEOFORMULA®1-ADIPOSITY has no level of toxicity due to the attenuation of the ingredients.

14. CLINICAL STUDIES

14.1.    OMEOFORMULA®1-ADIPOSITY formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic description as refer in Materia Medica.

15. REFERENCES

15.1.    E.Italia, M. De Bellis: Manuale di Omeo-mesoterapia – Guna Ed. 1995.

15.2.    H.H.Reckeweg: Homeopathic Materia Medica omeopatica. Aurelia Verlag.

16. HOW SUPPLIED/STORAGE AND HANDLING

16.1.    NDC  17089-272-31  10 glass vials packed in carton box

16.2.    NDC  17089-272-32  50 glass vials packed in carton box

16.3.    Store at room temperature, 20-25°C (68-77° F). Avoid  freezing  and  excessive  heat.

17. PATIENT COUNSELING INFORMATION

17.1.    Patients should be informed of the homeopathic approach and OMEOFORMULA®1-ADIPOSITY therapeutic goals.

PACKAGE LABEL

OMEOFORMULA1-ADIPOSITY  .alpha.-ketoglutaric acid - aconitic acid, cis - barium cation - calcium fluoride - citric acid monohydrate - fucus vesiculosus - fumaric acid - lard - magnesium gluconate - malic acid - manganese phosphate, dibasic - niacinamide - sarsaparilla - silybum marianum seed - sodium diethyl oxalacetate - sodium pyruvate - succinic acid - sulfur - sus scrofa artery - sus scrofa pituitary gland - thyroid -   injection, solution

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 17089-272 Route of Administration INTRADERMAL, SUBCUTANEOUS, INTRAMUSCULAR DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LARD (LARD) LARD 10 [hp_X]  in 2 mL .ALPHA.-KETOGLUTARIC ACID (.ALPHA.-KETOGLUTARIC ACID) .ALPHA.-KETOGLUTARIC ACID 6 [hp_X]  in 2 mL SUS SCROFA ARTERY (SUS SCROFA ARTERY) SUS SCROFA ARTERY 6 [hp_X]  in 2 mL BARIUM OXALOSUCCINATE (BARIUM OXALOSUCCINATE) BARIUM OXALOSUCCINATE 6 [hp_X]  in 2 mL CALCIUM FLUORIDE (CALCIUM FLUORIDE) CALCIUM FLUORIDE 30 [hp_X]  in 2 mL SILYBUM MARIANUM SEED (SILYBUM MARIANUM SEED) SILYBUM MARIANUM SEED 6 [hp_X]  in 2 mL ACONITIC ACID, CIS- (ACONITIC ACID, CIS-) ACONITIC ACID, CIS- 6 [hp_X]  in 2 mL CITRIC ACID MONOHYDRATE (ANHYDROUS CITRIC ACID) CITRIC ACID MONOHYDRATE 6 [hp_X]  in 2 mL MALIC ACID (MALIC ACID) MALIC ACID 6 [hp_X]  in 2 mL FUCUS VESICULOSUS (FUCUS VESICULOSUS) FUCUS VESICULOSUS 30 [hp_X]  in 2 mL FUMARIC ACID (FUMARIC ACID) FUMARIC ACID 6 [hp_X]  in 2 mL SUS SCROFA PITUITARY GLAND (SUS SCROFA PITUITARY GLAND) SUS SCROFA PITUITARY GLAND 30 [hp_X]  in 2 mL MAGNESIUM GLUCONATE (MAGNESIUM CATION) MAGNESIUM GLUCONATE 6 [hp_X]  in 2 mL MANGANESE PHOSPHATE, DIBASIC (MANGANESE PHOSPHATE, DIBASIC) MANGANESE PHOSPHATE, DIBASIC 6 [hp_X]  in 2 mL SODIUM DIETHYL OXALACETATE (DIETHYL OXALACETATE) SODIUM DIETHYL OXALACETATE 6 [hp_X]  in 2 mL SODIUM PYRUVATE (PYRUVIC ACID) SODIUM PYRUVATE 6 [hp_X]  in 2 mL NIACINAMIDE (NIACINAMIDE) NIACINAMIDE 6 [hp_X]  in 2 mL SARSAPARILLA (SARSAPARILLA) SARSAPARILLA 6 [hp_X]  in 2 mL SUCCINIC ACID (SUCCINIC ACID) SUCCINIC ACID 6 [hp_X]  in 2 mL SULFUR (SULFUR) SULFUR 12 [hp_X]  in 2 mL THYROID (THYROID) THYROID 10 [hp_X]  in 2 mL

Inactive Ingredients Ingredient Name Strength SODIUM CHLORIDE 0.018 mL  in 2 mL WATER

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 17089-272-31 10 VIAL In 1 BOX contains a VIAL, GLASS 1 2 mL In 1 VIAL, GLASS This package is contained within the BOX (17089-272-31) 2 17089-272-32 50 VIAL In 1 BOX contains a VIAL, GLASS 2 2 mL In 1 VIAL, GLASS This package is contained within the BOX (17089-272-32)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved homeopathic		09/29/2006

Labeler - Guna spa (430538264)

Establishment
Name	Address	ID/FEI	Operations
Guna spa		430538264	manufacture

Revised: 06/2010Guna spa

Furasol

Furasol may be available in the countries listed below.

Ingredient matches for Furasol

Furazidin

Furazidin is reported as an ingredient of Furasol in the following countries:

• Latvia

International Drug Name Search

Atomirate

Atomirate may be available in the countries listed below.

Ingredient matches for Atomirate

Nicomol

Nicomol is reported as an ingredient of Atomirate in the following countries:

• Japan

International Drug Name Search

Zolben C

Zolben C may be available in the countries listed below.

Ingredient matches for Zolben C

Ascorbic Acid

Ascorbic Acid is reported as an ingredient of Zolben C in the following countries:

• Switzerland

Paracetamol

Paracetamol is reported as an ingredient of Zolben C in the following countries:

• Switzerland

International Drug Name Search

Pentoxifilina La Santé

Pentoxifilina La Santé may be available in the countries listed below.

Ingredient matches for Pentoxifilina La Santé

Pentoxifylline

Pentoxifylline is reported as an ingredient of Pentoxifilina La Santé in the following countries:

• Colombia

International Drug Name Search

Volox

Volox may be available in the countries listed below.

Ingredient matches for Volox

Levofloxacin

Levofloxacin is reported as an ingredient of Volox in the following countries:

• Indonesia

International Drug Name Search

Azatril

Azatril may be available in the countries listed below.

Ingredient matches for Azatril

Azithromycin

Azithromycin is reported as an ingredient of Azatril in the following countries:

• Bulgaria


• Estonia


• Georgia


• Latvia


• Lithuania

Azithromycin dihydrate (a derivative of Azithromycin) is reported as an ingredient of Azatril in the following countries:

• Slovakia

International Drug Name Search

Tau Kit

Tau Kit may be available in the countries listed below.

Ingredient matches for Tau Kit

Urea

Urea ?1?3C (a derivative of Urea) is reported as an ingredient of Tau Kit in the following countries:

• Spain

International Drug Name Search

Soriatane

Soriatane is a brand name of acitretin, approved by the FDA in the following formulation(s):

SORIATANE (acitretin - capsule; oral)

• 
  Manufacturer: STIEFEL LABS INC
  
  Approval date: October 28, 1996
  
  Strength(s): 10MG, 25MG ^[RLD]


• 
  Manufacturer: STIEFEL LABS INC
  
  Approval date: August 6, 2009
  
  Strength(s): 17.5MG, 22.5MG
  

Has a generic version of Soriatane been approved?

No. There is currently no therapeutically equivalent version of Soriatane available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Soriatane. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Soriatane.

See also...

• Soriatane Consumer Information (Wolters Kluwer)
• Soriatane Consumer Information (Cerner Multum)
• Soriatane Advanced Consumer Information (Micromedex)
• Soriatane AHFS DI Monographs (ASHP)
• Acitretin Consumer Information (Wolters Kluwer)
• Acitretin with Moisturizer Consumer Information (Wolters Kluwer)
• Acitretin Consumer Information (Cerner Multum)
• Acitretin Advanced Consumer Information (Micromedex)
• Acitretin AHFS DI Monographs (ASHP)